Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The invention relates to the therapeutic or prophylactic treatment of fungal infections. The invention provides new methods for therapeutically or prophylactically treating fungal infections using sub-lethal concentrations of an anti-invasin compound. The methods according to the invention have fewer toxicology problems than existing methods, and thus can be used prophylactically, as well as for early treatment for high risk patients without a firm diagnosis. The methods according to the invention can also be used to treat an established fungal infection. The invention further provides novel genes that regulate fungal hyphal growth.

Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Abstract: The invention provides BASB203 polypeptides and polynucleotides encoding BASB203 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

Abstract: The present application provides GB virus C sequences (GBV-C or hepatitis G virus) and methods of using the sequences.

Abstract: An oligonucoeotide selected from the group consisting of ISN2 (SEQ ID NO: 43), ISN2* (SEQ ID NO: 44), ISN (SEQ ID NO: 34), ISP2 (SEQ ID NO: 46), ISP2* (SEQ ID NO: 45) and ISP (SEQ ID NO: 33).

Abstract: Inhibitors of human Sos1, including antisense oligonucleotides, methods, and compositions specific for human Sos1, are provided. Methods of using the compositions for modulating Sos1 expression and for regulating cell growth, particularly tumor cell growth, are also provided.

Abstract: The present invention is directed to the process for the preparation of 2?-deoxy-2?-halo-?-L-arabinofuranosyl nucleosides, and in particular, 2?-deoxy-2?-fluoro-?-L-arabinofuranosyl thymine (L-FMAU), from L-arabinose, which is commercially available and less expensive than L-ribose or L-xylose, in ten steps. All of the reagents and starting materials are inexpensive and no special equipment is required to carry out the reactions.

Abstract: Novel discotic liquid crystalline porphyrins and discotic liquid crystalline metal complexes, methods for their preparation, and device fabrication are disclosed. Materials with partially perfluorinated alkyl group in the peripheral chains show a strong tendency towards the formation of homeotropic alignment. These compounds are capable of being used as high-efficiency photovoltaic materials, organic semiconducting materials, and organic light emitting materials.

Abstract: The present invention is directed to a compound of formula I: wherein R1 and R2 are independently selected from H, halogen, protected or unprotected hydroxy, alkylsilyloxy, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted alkoxy or aryloxy, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, nitro, amino, mercapto or alkylthio; R3 and R4 are independently selected from H, substituted alkyl, substituted or unsubstituted alkoxy or aryloxy, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl; Z is —(CRaRb)n— wherein n is a number selected from 1, 2, 3 and Ra and Rb are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted amino or halogen; Y is

Abstract: The present invention provides a process for the preparation of phenylacetic acid compounds 2 where R2 is an optionally substituted aryl, R6 is NO2, NH2, alkyl, halogen, or a function group readily derived there from and R4a is hydrogen C1-6 alkyl, tert-butyl or benzyl The compounds of formula 2a are useful intermediates for the preparation of HIV reverse transcriptase inhibitors

Abstract: Pyrimidine compounds of formula (1): wherein R1 is C3-C7 alkynyl optionally substituted with halogen; R2 and R3 are independently hydrogen or the like; and R4 is C3-C7 alkynyloxy optionally substituted with halogen, optionally substituted phenyl, or the like have an excellent pesticidal effect.

Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain.

Abstract: The present invention is directed to novel fused pyrrolocarbazoles and isoindolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.

Abstract: Disclosed are substituted tricyclic heterocycle compounds of the formulas (I), (II) and (III) shown below, wherein R1, R2, R3 and R4 are described herein, which are active as anti-inflammatory agents.

Abstract: N-(4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridin-2-yl)-(C6-18)arylsulfonamides, wherein the nitrogen atom of the pyridine is substituted, and wherein the pyridine ring is optionally bridged, useful as a pharmaceutical related to steroid sulfatase

Abstract: The present invention relates to a novel process for the manufacture of blood-platelet aggregation inhibiting agent. In particular, the present invention is directed to a process for the manufacture of Methyl-(+)-(S)-?-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-S-(4H)acetate bisulfate Form-I.

Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor

Abstract: A class of binding ligands for cocaine receptors and other receptors in the brain. Specifically, a novel family of compounds shows high binding specificity and activity, and, in a radiolabeled form, can be used to bind to these receptors, for biochemical assays and imaging techniques. Such imaging is useful for determining effective doses of new drug candidates in human populations. In addition, the high specificity, slow onset and long duration of the action of these compounds at the receptors makes them particularly well suited for therapeutic uses, for example as substitute medication for psychostimulant abuse. Some of these compounds may be useful in treating Parkinson's Disease or depression, by virtue of their inhibitory properties at monoamine transporters.

Abstract: The present invention provides compounds, for example, of formula (I): wherein R1, R2, and R3 have any of the values defined in the specification, as well as pharmaceutical compositions comprising the compounds. The invention also provides therapeutic methods, and processes and intermediates useful for preparing compounds of formula I.

Abstract: A chiral catalyst comprising a 3, 4-disubstituted pyridine, or a salt, N functionalised derivative, dimer or oligomer thereof, wherein the 3-substituent is substantially hindered from rotation about the bond (sp2-sp2 biaryl axis) linking it to pyridine and the 4-substituent is an aliphatic or aromatic amine linked by a single bond to the pyridine, the pyridine nitrogen being functionalised or unfunctionalised, preferably comprising a compound of formula I wherein Z is a group substantially hindered from rotation about its bond; and each of R1 and R2 are independently selected from C1-30 alkyl, C3-30 cyclo alkyl and/or C3-30 aryl, or NR1 R2 form a cyclic amine; wherein R1 and/or R2 may be optionally substituted and/or include one or more heteroatoms; a composition or support comprising the catalyst; process for the preparation and resolution thereof; process for stereoselective reaction of an optically inactive substrate using the catalyst; and the optically active reaction product thereof.

Abstract: Disclosed are 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione mesylate salts, or solvates thereof; processes for preparing such compounds, compositions comprising such compounds and the use of such compounds in medicine.

Abstract: The solution concerns a process of production of N-alkyl-2-benzthiazolylsulfeneimides by means of a reaction of 2-benzthiazolylsulfenyl chloride with an excess of a corresponding alkylamine in an anhydrous reaction medium. Removement of water and moisture from the reaction medium is ensured by azeotropic distillation of a part of the solvent. The method solves also trapping of the excess amine by extraction with water to recycle it in the process, removing of the unconverted raw material from the crude product by chemical refining with aqueous lye and extraction of by-products and pitches by elutriating the product in an organic solvent with the aim to obtain pure benzthiazolylsulfeneimide containing no less than 95% of the active substance, which can be used as a vulcanization accelerator in ruber mixtures.

Abstract: A process for the preparation of benzo[d]isoxazol-3-yl-methanesulfonic acid of formula (I), or a salt thereof, and the intermediates thereof, useful as an intermediate in the preparation of zonisamide.

Abstract: A series of isoxazole derivatives and methods of suppressing, inhibiting, or preventing disorders mediated by nitric oxide (NO) and/or proinflammatory cytokines, such as TNF-? (tumor necrosis factor alpha), IL-1 (interlukin-1), and IL-6, are described.

Abstract: The present application describes modulators of chemokine receptors of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

Abstract: A process for preparing perindopril is provided comprising condensing an N-[(S)-1-carbethoxybutyl]-(S)-alanyl halide of formula II: wherein X is a halide with an (2S,3aS,7aS)-2-carboxyperhydroindole of formula III: wherein R is hydrogen or a protecting group.

Abstract: A process for obtaining the pharmaceutical active ingredient, levetiracetam, by means of deaminomethylation of a sufficiently pure enantiomer intermediate (S)-(II), or by means of deaminomethylation of an addition salt thereof with an acid, wherein R1 and R2 are either the same or different (C1-C6)-alkyl radicals, or else R1 and R2 together with the nitrogen atom to which they are bonded form a radical selected from the group consisting of 1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, 1-piperazinyl and 1-[4-(C1-C4)-alkylpiperazinyl]. The invention also comprises preparing the sufficiently pure enantiomer intermediate (S)-(II) by treating the corresponding chemically new racemic intermediate (II) with an amine resolving agent, followed by selective crystallisation of a diastereoisomeric salt thereof.

Abstract: An organic silicon compound, having high reactivity, represented by the following Formula (1): wherein R and M are defined in the specification. The organic silicon compound is produced by reacting polysilsesquioxane, which is obtained by hydrolyzing a silane compound having three hydrolyzable groups and represented by the following Formula (2), with a monovalent alkaline metal hydroxide in an organic solvent, or by subjecting the silane compound having three hydrolyzable groups to hydrolysis and polycondensation in the presence of an organic solvent and an alkaline metal hydroxide: R—Si X3??(2) wherein R is the same as in Formula (1) and X represents a hydrolyzable group.

Abstract: Ester mixture comprising at least one ester of an aliphatic or aromatic di- or tricarboxylic acid having a C10 alcohol component composed of 2-propylheptanol or composed of a C10 alcohol mixture composed of 2-propylheptanol and of at least one of the C10 alcohols 2-propyl-4-methylhexanol, 2-propyl-5-methylhexanol, 2-isopropylheptanol, 2-isopropyl-4-methylhexanol, 2-isopropyl-5-methylhexanol, and/or 2-propyl-4,4-dimethylpentanol, and comprising at least one ester of an aliphatic or aromatic di- or tricarboxylic acid having a C7 alcohol component composed of n-heptanol or composed of an alcohol mixture composed of n-heptanol with at least one of the C7 alcohols 2-methylhexanol and/or 2-ethylpentanol, where the aliphatic or aromatic di- or tricarboxylic acid has been selected from the group consisting of citric acid, phthalic acid, isophthalic acid, terephthalic acid, and trimellitic acid, and polyvinyl chloride composition comprising this ester mixture.

Abstract: A method is described for preparing astaxanthin esters from zeaxanthin by acylation of zeaxanthin with an acylating agent followed by contacting the esterified zeaxanthin with an oxidizing agent to produce esterified astaxanthin. The astaxanthin esters are more stable and show a better bioavailability than free astaxanthin when used in salmonid pigmentation.

Abstract: A method for dehydrogenofluorination for transforming an aromatic carbamoyl fluoride into a corresponding isocyanate, is provided. The method includes subjecting a carbamoyl fluoride to a temperature not less than 80° C. in a solvent wherein the carbamoyl fluoride is in a dissolved or finely dispersed state in the solvent. The method is applicable to organic synthesis.

Abstract: This invention relates to the use of a supplemental promoter in conjunction with a noble-metal-containing catalyst comprising a carbon support in catalyzing liquid phase oxidation reactions, a process for making of an improved catalyst comprising such a supplemental promoter, and an improved catalyst comprising such a supplemental promoter. In a particularly preferred embodiment, a supplemental promoter (most preferably bismuth or tellurium) is used in conjunction with a noble-metal-containing catalyst comprising a carbon support in a liquid phase oxidation process wherein N-(phosphonomethyl)iminodiacetic acid (i.e., “PMIDA”) or a salt thereof is oxidized to form N-(phosphonomethyl)glycine (i.e., “glyphosate”) or a salt thereof. The benefits of such a process include increased oxidation of the formaldehyde and formic acid by-products, and, consequently, decreased final concentrations of those by-products as well as other undesirable by-products, most notably N-methyl-N-(phosphonomethyl)glycine (i.e.

Abstract: A production method of an optically active ?-amino acid represented by the formula (I) wherein each symbol is as defined in the specification, which includes reacting a compound represented by the formula (II) with a lithium amide represented by the formula (III) in the presence of a compound represented by the formula (IV).

Abstract: The invention relates to a process for the reduction of compounds comprising a carbon-carbon (C?C), carbon-oxygen (C?O), or carbon-nitrogen (C?N) double bond, to a corresponding hydrogenated alkane, alcohol or amine, comprising contacting a compound comprising the C?C, C?O or C?N double bond with a hydrogen donor solvent and a catalyst comprising a metal complex having a tridentate aminodiphosphine ligand under transfer hydrogenation conditions.

Abstract: Process for the catalytic hydrogenation of a nitrite in the presence of an amine and a catalyst wherein the catalyst is a liquid-rinsed Raney-type catalyst contacted with a hydroxide prior to contacting the catalyst with the amine. The process results in higher selectivity in the formation of diamines from diniriles.

Abstract: The present invention relates to a method for producing an alcohol and/or a ketone from a corresponding alkene(s) in a gas phase in the presence of water vapor by the use of an oxide catalyst. According to the present invention, there is provided a method for producing an alcohol and/or a ketone by bringing a starting material containing an alkene(s), as a gas phase into contact with an oxide catalyst in the presence of water vapor to carry out the reaction, wherein the oxide catalyst satisfies the following requirements: (a) it comprises an oxide(s) of molybdenum and/or tin, and (b) the amount of carbonaceous substances accumulated on the oxide catalyst is controlled to be within a range of 0.1 to 10% by mass, during the reaction.

Abstract: A method for producing a molecular compound which comprises mixing and kneading a solid host compound and a solid or liquid guest compound by using a kneader and optionally followed by extruding and granulating, wherein the method further comprises one or more of the steps of holding the product at a temperature which is 50° C. or higher and not higher than the emission temperature for the guest compound, washing the formed molecular compound with a solvent capable of dissolving the guest compound, pulverizing in advance the solid host compound, and adding a poor solvent such as water prior to mixing and kneading. The method allows the production of a molecular compound having improved stability.

Abstract: The invention relates to a method for the production of 1,2-dichloroethane by direct chlorination using chlorine and ethene in which, despite low reaction temperatures during direct chlorination, reaction heat produced is nevertheless used. According to the invention, vaporous 1,2-dichloroethane obtained in the direct chlorination reactor is compressed and the compressed 1,2-dichloroethane is transported to heat exchangers whereby heat is given off by the 1,2-dichloroethane. The invention also relates directly after the direct chlorination reactor.

Abstract: The present invention relates to a process for the production of highly reactive polyisobutenes with a content of terminal vinylidene groupings of greater than 80 mol % and an average molecular weight of 500 to 10,000 Dalton by cationic polymerization of isobutene or of isobutene and monomers copolymerizable with isobutene in the presence of solvent-stabilized transition metal complexes with weakly coordinated anions.

Abstract: Process for oligomerizing an alkene stream over a solid catalyst comprising sulfur and nickel, in which the oligomerization is carried out in two or more successive catalyst zones and the molar ratio of sulfur to nickel in the first catalyst zone is less than 0.5 and that in the last catalyst zone is 0.5 or more and, in the case of further catalyst zones between the first and last catalyst zones, the molar ratio of sulfur to nickel in each catalyst zone is not less than that in the immediately preceding catalyst zone, based on the main flow direction of the feed stream.

Abstract: A process for the production of an olefin comprising partially combusting in a reaction zone a mixture of a hydrocarbon and an oxygen-containing gas in the presence of a catalyst which is capable of supporting combustion beyond the fuel rich limit of flammability to produce the olefin, wherein the superficial feed velocity of said mixture is at least 250 cm s?-1? at standard temperature and operating pressure with the proviso that where the catalyst is an unsupported catalyst, the superficial feed velocity of said mixture is at least 300 cm s?1 at standard temperature and operating pressure.

Abstract: A process for the continuous heterogeneously catalyzed partial dehydrogenation of a hydrocarbon in the gas phase and in the presence of molecular oxygen, in which part of the product gas is recirculated to the reaction zone, and a reactor for carrying out such a process.

Abstract: A dressing for promoting healing and pain relief of the body of a living organism having a pathologic condition has at least one layer of conductive material having a resistance no greater than 1000 ?/cm2. When placed proximate a portion of the body of the living organism suffering from the pathologic condition, the dressing alters the electrodynamic processes occurring in conjunction with said pathologic condition to promote healing and pain relief in the living organism. When used as a wound dressing, the conductive material is placed in contact with tissue around the periphery of the wound and with the wound, lowering the electrical potential and resistance of the wound and increasing the wound current. In an exemplary embodiment, the conductive material is a multi-ply nylon fabric plated with silver by an autocatalytic electroless plating process and with the plies in electrical continuity. The dressing provides an antimicrobial and analgesic effect.

Abstract: Absorbent articles which provide superior protection against wet through under impact or sustained pressure, and high convective air flow therethrough for skin health and comfort benefits. An absorbent article comprising an absorbent core and an absorbent barrier structure, wherein the absorbent barrier structure has a hydrohead value of at least about 10 mBars; a convective air permeability of at least about 10 Darcy/mm; and a liquid impact transmission value of less than about 20 g/m2.

Abstract: An improved method of nuclear transfer involving the transplantation of donor differentiated pig cell nuclei into enucleated pig oocytes is provided. The resultant nuclear transfer units are useful for multiplication of genotypes and transgenic genotypes by the production of fetuses and offspring. Production of genetically engineered or transgenic pig embryos, fetuses and offspring is facilitated by the present method since the differentiated cell source of the donor nuclei can be genetically modified and clonally propagated.

Abstract: The promoters of a soybean seed maturation protein PM29 and a soybean late-embryogenesis abundant protein LEA3 and fragments thereof and their use in promoting the expression of one or more heterologous nucleic acid fragments in plants are described.

Abstract: The invention provides methods of modulating seed mass and other traits in plants. The methods involve producing transgenic plants comprising a recombinant expression cassette containing an ADC nucleic acid linked to a plant promoter.

Abstract: This invention relates to putative known and unknown deoxyribonucleic acid (DNA) and amino acid sequences identified in one or more metabolic pathways that lead to dwarfism and stunting in plants and the use of these sequences in agriculture to create dwarf varieties of any plant species. This invention also relates to nucleic acids sequences and polypeptides that produce altered metabolism phenotypes in plants.